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Introduction
The use of bisphosphonates combined with antineoplastic
chemotherapeutic agents is considered a standard in the
treatment of hypercalcemia associated with malignancy
and of metastatic osteolytic lesions associated with breast
cancer and multiple myeloma [1, 2]. More recently, the
indications for bisphosphonate treatment have been
extended to osteolytic lesions caused by any solid tumor.
This has resulted in a rapid increase of consumption of
bisphosphonates in the majority of medical oncology
practices within the past several years. Pamidronate and
zoledronic acid are licensed for use in multiple myeloma
with bone lesions. However, they are widely applied off
label in patients without bone lesions, and often in
smoldering disease.
Jaw osteonecrosis has recently been identified as
a complication in bisphosphonate–treated patients [3-7].
Ruggiero et al [8] have performed a retrospective chart
review of patients who presented to their Oral Surgery
service between February 2001 and November 2003 with
the diagnosis of refractory osteomyelitis and a history of
chronic bisphosphonate therapy. Sixty three patients have
been identified with such a diagnosis. Fifty-six patients
had received intravenous bisphosphonates (pamidronate
34, zoledronic acid 9, pamidronate and zoledronic acid
13) for at least 1 year. The most common oncologic
diagnoses at presentation were multiple myeloma
(28 patients) and breast cancer (20 patients), followed
by prostate cancer (3 patients), lung cancer (1 patient),
uterine leiomyosarcoma (1 patient), plasmocytoma
(1 patient) and leukemia (1 patient). Seven patients with
a diagnosis of osteoporosis were on chronic oral
alendronate (6 patients) and risedronate (1 patient)
therapy and had no history of malignant disease or
chemotherapy exposure. The typical presenting lesions
were either a nonhealing extraction socket or an exposed
jawbone; both were resistant to conservative debridement
and antibiotic therapy. Biopsy of these lesions has shown
no evidence of metastatic disease. A majority of these
patients required surgical procedures to remove the
involved bone.
In a study of Singhal et al [9] 15 cases of jaw
osteonecrosis were identified among 650 myeloma
patients (incidence 2.5%) seen between March 2001 and
August 2004. All patients were on pamidronate (4
patients) or zoledronic acid (11 patients) at standard
doses when osteonecrosis was diagnosed. The duration of
bisphosphonate therapy prior to the development of
symptoms ranged from 4 to 75 months (median 50). The
outstanding symptom was local pain and discomfort, and
bone protrusion within the oral cavity.
Thakkar et al [10] have reported 16 cases of multiple
myeloma treated with bisphosphonates in which patients
had developed periodontitis/osteomyelitis of the jaw. All
were treated with bisphosphonates for an average of
8 months (range 4-17 months) prior to the onset of new
jaw symptoms. Six patients were receiving zoledronic acid
and 10 – pamidronate.
Woo et al. have seen more than 20 cases of osteo-
necrosis of the jaw in patients with myeloma at their
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institution over a period of six months, although they had
observed very few such cases in previous years [11].
In a study of Maerevoet et al [12], 9 cases of biopsy-
proven osteonecrosis of the jaw were diagnosed at their
institution between December 2003 and July 2004 (4 in
patients with multiple myeloma and 5 in patients with
metastatic breast cancer) among 194 patients treated with
zoledronic acid (4.6%). Before receiving zoledronic acid,
6 of those 9 patients had been treated first with
pamidronate (90 mg every three or four weeks). The
median duration of treatment with pamidronate was 39
months (range, 4 to 58). For zoledronic acid, the median
duration of therapy before the appearance of osteo-
necrosis was 18 months (range, 4 to 22), and the median
cumulative dose was 72 mg (range, 36 to 88).
In 2004, the International Myeloma Foundation
conducted a Web-based survey to assess the risk factors
for osteonecrosis of the jaw. Of 1203 respondents, 904
had myeloma and 299 breast cancer. Both osteonecrosis
and suspicious findings, including bone erosions and spurs
plus exposed bone were assessed. Sixty-two patients with
myeloma had osteonecrosis of the jaw and 54 had
suspicious findings; 13 patients with breast cancer had
osteonecrosis and 23 had suspicious findings – a total of
152 patients with either osteonecrosis or suspicious
findings. It was found that osteonecrosis of the jaws was
most strongly associated with use of pamidronate and/or
zoledronic acid. Of the patients with myeloma, 71% had
received zoledronic acid and 29% had received only
pamidronate. This risk was time – dependent and became
significant at 12 months, increasing thereafter to 36
months. With data censored at 36 months, the estimated
incidence of osteonecrosis among patients receiving
zoledronic acid was 10% and that among those receiving
pamidronate was 4% [13, 14].
The aim of the paper is to present two cases
of multiple myeloma who had developed jaw and
dental complications most likely associated with the
administration of a third generation bisphosphonate –
zoledronic acid. These complications have already drawn
our attention earlier [3].
Case reports
C a s e  1
A 56-year – old man was diagnosed with multiple
myeloma in 1998 on the base of plasma cells in the bone
marrow increased up to 56%, generalised osteolysis and
the presence of monoclonal protein IgGκ in the serum.
Apart from anti-myeloma therapy initially performed
with melphalan, and continued until the present
(September 2005) with chemotherapy according to the
VMCP/VBAP regimen, between 1999 and 2000 the
patient had also been treated with zoledronic acid. This
bisphosphonate was systematically administered every
month as an intravenous infusion in a single dose of 8 mg.
Altogether 18 cycles were administered. In 2000 the
patient had also been irradiated to the spinal cord.
In 1999 it became necessary to remove the majority
of his carietic teeth and roots. The patient’s alveolus
healed. During a number of months after the installation
of denture he developed a wound in the gum from which
the protruding bone occasionally found to be crumbling.
During two subsequent years the alveolar part of the
lower jaw bone remained uncovered. An X–ray survey
of the mandible revealed destruction of bone texture with
a tendency to a form of sequestration of the destroyed
bone (Figure 1). Biopsy of these lesions provided no
evidence of malignancy. Bone destruction progressed.
In 2004 osteolytic changes appeared and the body of the
mandible fractured (Figure 2) opening a mandibular
fistula. Cultures from the mandibular lesions revealed
the changing presence of different bacteria: Staphylo-
coccus epidermidis, Streptococcus salivarius ssp.salivarius,
Morganella morgani, Prevotella intermedia/disiens,
Prevotella oris buccae, Escherichia coli and anaerobic
Gram-negative species. The treatment of mandibular
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Figure 1. Mandible osteonecrosis in a patient treated with zoledronic
acid 8 mg monthly
Figure 2. Mandible of the patient treated with zoledronic acid 8 mg
monthly three years later. The body of the mandible fractured and
osteolytic lesions occurred
lesions included antibiotic administration according
toculture results, sequestrectomy of the bone in the
alveolar part of the mandible to the right side of teeth 47
and 46 (October 2002), and later, after the development
of osteolytic lesions, irradiation to the mandible. At
present, 61 months after the end of zoledronic acid
administration non healing lesions in the oral cavity
continue to remain a serious therapeutic problem.
C a s e  2
A 55 – year – old patient with multiple myeloma
diagnosed basing upon bone marrow plasma cell rate
increased up to 29%, skull and rib osteolysis and the
presence of M-protein IgAλ in the serum. VMCP/VBAP
treatment led into remission in 1999. Apart from
chemotherapy during the years 1999-2000 the patient had
been administered zoledronic acid in a dose of 4 mg as
intravenous infusions every month altogether amounting
to 18 cycles. In 2000 it was necessary to perform to extract
carietic teeth and prepare dentures. After just over a year
the patient developed painful bone exposure in the
alveolar part of the mandible. No osteolytic changes were
found within the jaws (Figure 3). This lesion proved
resistant to any form of dental treatment, including
surgical removal of necrotic tissue and administration of
numerous antibiotics according to the results of cultures
obtained from the lesion. The lesion persisted until the
patient’s death among symptoms of pancytopenia and
sepsis 27 months after completing zoledronic acid
administration and 47 months after the diagnosis of
multiple myeloma.
Discussion
Bisphosphonates are powerful osteoclast inhibitors with
antiangiogenic properties and a half-life of many years
(15). The potent bisphosphonate-mediated inhibition of
osteoclast function decreases bone resorption and inhibits
normal bone turnover remodeling, thus resulting in
microdamage accumulation and reduction of some
mechanical properties of bone [16-19). The mandible and
maxilla are generally bisphosphonate-seeking bones, as
evidenced by scintigraphy revealing increased bone
turnover with repetitive chewing motion. The role of
bisphosphonates in perpetuating infection is probably
multi-factorial. Angiogenesis inhibition may be involved,
as well as the prevention of debris clearance by osteoclasts
[20-22]. Also in myeloma the immune system tends to
become compromised, thus developing a fertile medium
for infection and further destruction. Additionally, in an
acidic environment, such as that potentially resulting from
infection, bisphosphonates are more rapidly released
from bone hydroxyapatites into the surrounding tissues
and are cytotoxic to the local stromal cells. As the
nitrogen containing bisphosphonates are rapidly released,
they may up-regulate the inflammatory response by
stimulating IL-1 and IL-6. As more inflammation ensues
there is more release of bisphosphonates. This continuous
cycle perpetuates an unstable local environment [4, 8, 10].
The pathogenesis of the osteonecrotic process is
rather consistent with localized vascular insufficiency [4-
6, 8, 23]. Osteonecrosis of the jaw probably results from
the inability of the hypodynamic and hypovascular bone to
meet the increased demand for repair and remodeling
owing to physiologic stress (mastication), iatrogenic
trauma (tooth extraction or denture injury), or tooth
infection in an environment that is trauma-intense and
bacteria–laden. Coexisting factors may include the use
of other medications with antiangiogenic properties, such
as glucocorticoids, thalidomide, and bortezomib in
patients with myeloma and other factors, such as diabetes
mellitus, irradiation of the jawbone, peripheral vascular
disease and hyperviscosity syndrome [11].
The management of patients with bisphosphonate-
related osteonecrosis is difficult, as we have also shown in
the case reports. Radical resection appears to be of
limited use in cases of osteonecrosis of the jaw and may
be contraindicated; the disease may progress despite
surgery and cessation of bisphosphonate therapy [8].
The efficacy and safety of clodronate (24),
pamidronate (25) and zoledronic acid (3) in the treatment
of myeloma bone disease have been evaluated in
a prospective study performed at our institution. In none
of the cases treated with clodronate or pamidronate did
we observe osteonecrosis of the jaws. However, in our
study we had aministered pamidronate in a dose of 60 mg,
intravenously, every month, and not in a dose of 90mg as
it had been used by other authors who had reported the
occurrence of jaw osteonecrosis in patients receiving
pamidronate [9, 10, 12]. In our studies osteonecrosis of
the jaws developed in 2 out of 6 patients treated with
zoledronic acid [3]. Literature data also proves that osteo-
necrosis of the jaws has been most commonly observed in
patients receiving zoledronic acid [7, 9, 12, 14].
Finally, it is worth to note that clinicians should be
aware of the possibility of implant failure and delayed
wound healing, especially in patients receiving intravenous
bisphosphonates for malignant tumors. Dental implant
failures attributable to oral bisphosphonate therapy have
been reported in patients with osteoporosis [26, 27].
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Figure 3. Mandible lesions in a patient treated with zoledronic acid
4 mg monthly
Conclusions
Bisphosphonate use can be associated with jaw or dental
problems, including pain, bone necrosis and poor healing.
These problems are more likely to occur after longer
periods of bisphosphonate use and after the application of
more potent bisphosphonates e.g. zoledronic acid. The
risk is increased by major dental procedures and poor
dental hygiene. Early diagnosis might prevent or reduce
the morbidity resulting from destructive lesions of the
jaw bones. Complete dental evaluation and treatment
should be performed prior to the onset of bisphosphonate
therapy. Once bisphosphonate therapy has begun, dental
extractions, placement of dental implants and any other
interventions must be undertaken with due caution. Major
surgical interventions should be avoided. It is recommen-
ded to withdraw bisphosphonates for a period of at least
3 months prior to invasive dental procedures to allow for
the recovering of osteoclastic activity, removing debris
and reducing the chance of creating a fertile bacterial
medium. In patients with multiple myeloma on bisphos-
phonate therapy who report dental/jaw discomfort
a careful examination (including jaw imaging in case of
any local symptoms) should be performed to exclude
infectious etiology. Patients receiving bisphosphonates
who have developed dental infections, should be taken
of biphosphonate therapy until the infection is controlled.
In patients developing jaw osteonecrosis, not only
bisphosphonates, but also potential co-factors or co-
triggering factors should be stopped or avoided. If it is at
all feasible, steroids such as prednisone or dexamethasone
should be discontinued or reduced. There should be no
irradiation therapy involving the head and neck. It is very
important to carefully assess the need for bisphosphonate
therapy and to avoid their administration in plasma cell
dyscrasias, where their usefulness has not been established
yet (e.g. smoldering myeloma). One should also
remember that with the extension of treatment duration
the effect of bisphosphonates on skeletal morbidity
becomes less pronounced [25, 28].
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